Format

Send to

Choose Destination
Drug Discov Today. 2017 Nov;22(11):1707-1718. doi: 10.1016/j.drudis.2017.06.007. Epub 2017 Jul 4.

Mouse models of nonalcoholic steatohepatitis in preclinical drug development.

Author information

1
Gubra Aps, Hørsholm Kongevej 11b, Hørsholm DK-2970, Denmark. Electronic address: hbh@gubra.dk.
2
Gubra Aps, Hørsholm Kongevej 11b, Hørsholm DK-2970, Denmark.

Abstract

Nonalcoholic fatty liver disease (NAFLD) has become the most common cause of chronic liver disease in the Western world. NAFLD is a complex spectrum of liver diseases ranging from benign hepatic steatosis to its more aggressive necroinflammatory manifestation, nonalcoholic steatohepatitis (NASH). NASH pathogenesis is multifactorial and risk factors are almost identical to those of the metabolic syndrome. This has prompted substantial efforts to identify novel drug therapies for correcting underlying metabolic deficits, and to prevent or alleviate hepatic fibrosis in NASH. Available mouse models of NASH address different aspects of the disease, have varying clinical translatability, and, therefore, also show different utility in drug discovery.

PMID:
28687459
DOI:
10.1016/j.drudis.2017.06.007
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center